Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' KEMPENI J' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 12 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Woodworth, TG; Furst, DE; Strand, V; Kempeni, J; Fenner, H; Lau, CS; Miller, F; Day, R; Lipani, J; Brooks, P
      Standardizing assessment of adverse effects in rheumatology clinical trials. Status of OMERACT Toxicity Working Group March 2000: Towards a common understanding of comparative toxicity/safety profiles for antirheumatic therapies

      JOURNAL OF RHEUMATOLOGY
    2. Reinhart, K; Menges, T; Gardlund, B; Zwaveling, JH; Smithes, M; Vincent, JL; Tellado, JM; Salgado-Remigio, A; Zimlichman, R; Withington, S; Tschaikowsky, K; Brase, R; Damas, P; Kupper, H; Kempeni, J; Eiselstein, J; Kaul, M
      Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study

      CRITICAL CARE MEDICINE
    3. Kempeni, J
      Update on D2E7: a fully human anti-tumour necrosis factor alpha monoclonalantibody

      ANNALS OF THE RHEUMATIC DISEASES
    4. Kempeni, J
      Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7

      ANNALS OF THE RHEUMATIC DISEASES
    5. RAU R; SANDER O; DENBROEDER A; VANRIEL PLCM; VANDERPUTTE L; KRUGER K; SCHATTENKIRCHER M; FENNER H; LASSMANN A; KUPPER H; KEMPENI J
      LONG-TERM EFFICACY AND TOLERABILITY OF MULTIPLE IV DOSES OF THE FULLYHUMAN ANTI-TNF-ANTIBODY D2E7 IN PATIENTS WITH RHEUMATOID-ARTHRITIS

      Arthritis and rheumatism
    6. VANDEPUTTE LBA; VANRIEL PLCM; DENBROEDER A; SANDER O; RAU R; BINDER C; KRUGER K; SCHATTENKIRCHER M; FENNER H; SALFELD J; BANKMANN Y; KUPPER H; KEMPENI J
      A SINGLE-DOSE PLACEBO-CONTROLLED PHASE-1 STUDY OF THE FULLY HUMAN ANTI-TNF ANTIBODY D2E7 IN PATIENTS WITH RHEUMATOID-ARTHRITIS

      Arthritis and rheumatism
    7. SCHATTENKIRCHNER M; KRUGER K; SANDER O; RAU R; KROOT EJ; VANRIEL PLCM; VANDEPUTTE L; FENNER H; KEMPENI J; KUPPER H
      EFFICACY AND TOLERABILITY OF WEEKLY SUBCUTANEOUS INJECTIONS OF THE FULLY HUMAN ANTI-TNF-ANTIBODY D2E7 IN PATIENTS WITH RHEUMATOID-ARTHRITIS- RESULTS OF A PHASE-I STUDY

      Arthritis and rheumatism
    8. REINHART K; WIEGANDLOHNERT C; GRIMMINGER F; KAUL M; WITHINGTON S; TREACHER D; ECKART J; WILLATTS S; BOUZA C; KRAUSCH D; STOCKENHUBER F; EISELSTEIN J; DAUM L; KEMPENI J
      ASSESSMENT OF THE SAFETY AND EFFICACY OF THE MONOCLONAL ANTITUMOR NECROSIS FACTOR ANTIBODY-FRAGMENT, MAK 195F, IN PATIENTS WITH SEPSIS AND SEPTIC SHOCK - A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGING STUDY

      Critical care medicine
    9. BOEHME MWJ; WALDHERR R; KIST A; RIEDL S; WALTERKIRST R; KEMPENI J; RAETH U
      KINETICS OF SOLUBLE TNF-RECEPTORS AND SOLUBLE ADHESION MOLECULES ICAM-1, E-SELECTIN AND VCAM-1 UNDER SYSTEMIC RHTNF-ALPHA THERAPY

      European journal of clinical investigation
    10. HOLLER E; KOLB HJ; MITTERMULLER J; KAUL M; LEDDEROSE G; DUELL T; SEEBER B; SCHLEUNING M; HINTERMEIERKNABE R; ERTL B; KEMPENI J; WILMANNS W
      MODULATION OF ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION BY TUMOR-NECROSIS-FACTOR-ALPHA (TNF-ALPHA) RELEASE IN THE COURSE OF PRETRANSPLANT CONDITIONING - ROLE OF CONDITIONING REGIMENS AND PROPHYLACTIC APPLICATION OF A MONOCLONAL-ANTIBODY NEUTRALIZING HUMAN TNF-ALPHA (MAK 195F)

      Blood
    11. BOEKSTEGERS P; WEIDENHOFER S; ZELL R; PILZ G; HOLLER E; ERTEL W; KAPSNER T; REDL H; SCHLAG G; KAUL M; KEMPENI J; STENZEL R; WERDAN K
      REPEATED ADMINISTRATION OF A F(AB')2 FRAGMENT OF AN ANTITUMOR NECROSIS FACTOR-ALPHA MONOCLONAL-ANTIBODY IN PATIENTS WITH SEVERE SEPSIS - EFFECTS ON THE CARDIOVASCULAR-SYSTEM AND CYTOKINE LEVELS

      Shock
    12. BOEKSTEGERS P; WEIDENHOFER S; ZELL R; HOLLER E; KAPSNER T; REDL H; SCHLAG G; KAUL M; KEMPENI J; WERDAN K
      CHANGES IN SKELETAL-MUSCLE PO2 AFTER ADMINISTRATION OF ANTI-TNF-ALPHA-ANTIBODY IN PATIENTS WITH SEVERE SEPSIS - COMPARISON TO INTERLEUKIN-6SERUM LEVELS, APACHE-II, AND ELEBUTE SCORES

      Shock


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 03/08/20 alle ore 12:55:18